New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus

B Diethelm-Varela, JA Soto, CA Riedel, SM Bueno, AM Kalergis

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Since the discovery of the human respiratory syncytial virus (hRSV), multiple research efforts have been conducted to develop vaccines and treatments capable of reducing the risk of severe disease, hospitalization, long-term sequelae, and death from this pathogen in susceptible populations. In this sense, therapies specifically directed against hRSV are mainly based on monoclonal and polyclonal antibodies such as intravenous IgG (IVIG)-RSV and the monoclonal antibody palivizumab. However, these therapies are associated with significant limitations, including the need for the recruitment of a high number of convalescent volunteers who donate blood to procure IVIG-RSV and the costs associated with the need for repeated administrations of palivizumab. These limitations render this product not cost-effective for populations other than high-risk patients. These problems have underscored that it is still necessary to identify new safe and effective therapies for human use. However, these new therapies must benefit from a comparatively cheap production cost and the opportunity to be available to the high-risk population and anyone who requires treatment. Here, we review the different antibodies used to prevent the pathology caused by hRSV infection, highlighting therapies currently approved for human use and their clinical value. Also, the new, most promising candidates based on preclinical studies and clinical trial results are revised.

Original languageEnglish
Pages (from-to)2061-2074
Number of pages14
JournalInfection and Drug Resistance
Publication statusPublished - 2023


  • antibodies
  • prevention
  • respiratory syncytial virus
  • treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus'. Together they form a unique fingerprint.

Cite this